A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT07105488 · tracked via the Priya Life Science Canada tracker

Sponsor

Bluefin Biomedicine, Inc

Phase

Phase 2

Started

2025-07-15

Last updated

2026-07-30

Condition(s) studied

Atopic Dermatitis (AD)

Investigational drug(s) / intervention(s)

BFB759 →Placebo

BFB759: BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis

Placebo: Placebo for BFB759

Study summary

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year. * Have moderate to severe disease not adequately controlled by topical treatments. * Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study. Exclusion Criteria: * Have certain infections or other immune conditions. * Recently used medications that could interfere with the study. * Are pregnant or breastfeeding.

Primary outcome measure(s)

Efficacy of BFB759 in AD — week 16 and week 32
To evaluate the efficacy of BFB759 in adult male and female participants with AD as assessed by Eczema Area and Severity Index (EASI) score. Measure improvements in redness, swelling, scratching damage, and roughness.

Trial sites (88)

Facility	City	Region
Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute	Phoenix	Arizona
Skin Cancer and Dermatology Institute	Phoenix	Arizona
T. Joseph Raoof Md, Inc	Encino	California
Marvel Clinical Research	Huntington Beach	California
Antelope Valley Clinical Trials	Lancaster	California
Probity Medical Research	Los Angeles	California
NorCal Clinical Research	Rocklin	California
Focus Clinical Research, LLC -S	West Hills	California
Skin Care Research	Boca Raton	Florida
Florida Academic Dermatology Center Res and Edu, LLC	Coral Gables	Florida
Center for Skin Science and Innovation	Fort Lauderdale	Florida
Gsi Clinical Research	Margate	Florida
Ziaderm Research LLC	North Miami Beach	Florida
Lenus Research & Medical Group, LLC	Sweetwater	Florida
Clinical Trials Management - S	Tampa	Florida
Conquest Research LLC	Winter Park	Florida
Skin Cancer and Dermatology Institute	Douglasville	Georgia
Southeast Research Specialists, LLC	Douglasville	Georgia
The Indiana Clinical Trials Center	Plainfield	Indiana
Clinical Trials Management - S	Covington	Louisiana
Clinical Trials Management, LLC	Metairie	Louisiana
MetroBoston Clinical Partners	Brighton	Massachusetts
Oakland Hills Dermatology	Auburn Hills	Michigan
MI Skin Innovations	Northville	Michigan
Medisearch, LLC	Saint Joseph	Missouri
Elias Research Associates	Missoula	Montana
JDR Dermatology Research	Las Vegas	Nevada
Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute	Reno	Nevada
Skin Cancer and Dermatology Institute	Reno	Nevada
Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute	Sparks	Nevada
Skin Cancer and Dermatology Institute	Sparks	Nevada
Schweiger Dermatology, PC R.D.	Hackensack	New Jersey
Bobby Buka, MD (The Dermatology Specialist)	New York	New York
Bobby Buka, MD	New York	New York
Equity Medical, LLC	The Bronx	New York
Vitality Clinical Trials LLC	Woodbury	New York
DJL Clinical Research	Charlotte	North Carolina
Optima Research-Boardman	Boardman	Ohio
Apex Clinical Research Center, LLC	Canton	Ohio
Apex Clinical Research Center, LLC	Mayfield Heights	Ohio

+ 48 more sites — see the full list on the official registry below.

More Bluefin Biomedicine, Inc. trials in Canada

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa Recruiting

Other trials for the same condition

Moisturization and Skin Hydration Study Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07105488 on ClinicalTrials.gov ↗ ← All trials in Canada